Aspergillus flavus Scleritis: successful treatment with voriconazole and caspofungin

References

• Patterson TF. Aspergillus species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 6th ed. Philadelphia: Churchill Livingstone 2005; 2958–2973.
   Google Scholar
• Richardson MD, Kokki M. Aspergillus. In: Anaissie EJ, McGinnins Dolin MR, Pfaller MA, eds. Clinical Mycology, 1st ed. Philadelphia: Churchill Livingstone, 2003; 273–296.
   Google Scholar
• Doft BH, Clarkson JG, Rebell G, Forster RK. Endogenous Aspergillus endophthalmitis in drug abusers. Arch Ophthalmol 1980; 98: 859–862
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Tessler HH. Episcleritis, scleritis, and other scleral disorders. In: Yanoff M, Duker JS, eds. Ophthalmology, 2nd ed. St Louis: Mosby, 2004; 511–519.
   Google Scholar
• Huang FC, Huang SP, Tseng SH. Management of infectious scleritis after pterygium excision. Cornea 2000; 19: 34–39
   PubMed Web of Science ®Google Scholar
• Stenson S, Brookner A, Rosenthal S. Bilateral endogenous necrotizing scleritis due to Aspergillus oryzae. Ann Ophthalmol 1982; 14: 67–72
   PubMed Web of Science ®Google Scholar
• Jager MJ, Chodosh J, Huang AJW, Alfonso EC, Culbertson WW, Forster RK. Aspergillus niger as an unusual cause of scleritis and endophthalmitis. Br J Ophthalmol 1994; 78: 584–586
   Google Scholar
• Hemady R, Sainz de la Maza M, Raizman MB, Foster CS. Six cases of scleritis associated with systemic infection. Am J Ophthalmol 1992; 114: 55–62
   PubMed Web of Science ®Google Scholar
• Rodriguez-Ares MT, De Rojas Silva MV, Pereiro M, , et al. Aspergillus fumigatus scleritis, Acta Ophthalmol Scand 1995; 73: 467–469.
   Google Scholar
• Carlson AN, Foulks GN, Perfect JR, Kim JH. Fungal scleritis after cataract surgery, successful outcome using itraconazole. Cornea 1992; 11: 151–154
   PubMed Web of Science ®Google Scholar
• Bernauer W, Allan BD, Dart JK. Successful management of Aspergillus scleritis by medical and surgical treatment. Eye 1998; 12: 311–316
   PubMed Web of Science ®Google Scholar
• Hsiao CH, Chen JJ, Huang SC, Ma HK, Chen PY, Tsai RJ. Intrascleral dissemination of infectious scleritis following pterygium excision. Br J Ophthalmol 1998; 82: 29–34
   PubMed Web of Science ®Google Scholar
• Garg P, Mahesh S, Bansal AK, Gopinathan U, Rao GN. Fungal infection of sutureless self-sealing incision for cataract surgery. Ophthalmology 2003; 110: 2173–2177
   PubMed Web of Science ®Google Scholar
• Kim JE, Perkins SL, Harris GJ. Voriconazole treatment of fungal scleritis and epibulbar abscess resulting from scleral buckle infection. Arch Ophthalmol 2003; 121: 735–737
   PubMedGoogle Scholar
• Reynolds MG, Alfonso E. Treatment of infectious scleritis and keratoscleritis. Am J Ophthalmol 1991; 112: 543–547
   PubMed Web of Science ®Google Scholar
• Chandler JW. Textbook of Ophthalmology. St Louis: Mosby, 1994; 13.1–13.12.
   Google Scholar
• Thomas PA. Current perspectives on ophthalmic mycoses. Clin Microbiol Rev 2003; 16: 730–797
   PubMed Web of Science ®Google Scholar
• Groll AH, Kolve H. Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur J Clin Microbiol Infect Dis 2004; 23: 256–270
   PubMed Web of Science ®Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142–1151
   PubMed Web of Science ®Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630–637
   PubMed Web of Science ®Google Scholar
• Sanati H, Belanger P, Fratti R, Ghannoum M. A new triazole, voriconazole (UK-109, 496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 1997; 41: 2492–2496
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003; 41: 3623–3626
   PubMed Web of Science ®Google Scholar
• Kakka R, Le H, Montoya JG. Clinical outcomes of combination therapy for invasive aspergillosis: experience at one academic center [Abstract 81]. In: Advances Against Aspergillosis. San FranciscoCA, 2004.
   Google Scholar
• Clemons KV, Espiritu M, Parmar R, Stevens DA. Combination therapy studies using Ambisome, Amphotericin B deoxycholate, caspofungin, micafungin and voriconazole against CNS aspergillosis [Abstract M-1140]. In: 44th Intersci. Conf. Antimicrob. Agents Chemother, Washington, DC, 2004.
   Google Scholar
• Munoz LS, Ruthazer R, Boucher H, Loudon S, Skarf L, Hadley S. Combination antifungals for primary treatment of invasive aspergillosis: do they work? [Abstract M-1024]. In: 44th Intersci. Conf. Antimicrob. Agents Chemother. Washington, DC, 2004.
   Google Scholar
• Meletiadis J, Petraitis V, Petraitiene R, , et al. Antagonistic interaction between liposomal amphotericin B and ravuconazole in experimental invasive pulmonary aspergillosis: implications for combination therapy [Abstract M-238]. In: 44th Intersci. Conf. Antimicrob. Agents Chemother. Washington, DC, 2004.
   Google Scholar